Literature DB >> 2963989

Response of individual adenovirus promoters to the products of the E1A gene.

C V Dery1, C H Herrmann, M B Mathews.   

Abstract

Adenovirus E1A genes possess transcriptional activation and repression activities. Three major gene products have been characterized, derived from the 13S, 12S and 9S mRNAs. Using transient expression assays in HeLa cells, we have investigated the effect of these gene products on the activity of the nine major Ad2 (or Ad5) promoters driving the expression of a reporter gene. Based on the results, we could separate the promoters into three classes: (a) E1A, which is active by itself, and is unaffected or slightly stimulated by the E1A 13S product (depending on the HeLa cell line used); (b) the other classical early promoters (E1B, E2e, E3, E4), all of which are active alone and are stimulated by the 13S product and repressed by the 12S product; and (c) the late promoters (IX, IVa2, MLP, E2L) which are not active alone and are substantially unaffected by the 13S or 12S products. Thus the 13S and 12S gene products have antagonistic effects on at least four adenovirus promoters. The 9S product did not influence the activity of any of the adenovirus promoters. Upon transfection into 293 cells, all the early promoters were active and all the late promoters were inactive, except for the major late promoter (MLP). We demonstrate that the combination of the E1A and E1B genes is a potent activator of the MLP in HeLa cells and discuss these results in the context of the infectious cycle.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963989

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses.

Authors:  Robin N Shepard; David A Ornelles
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Diverse roles for E4orf3 at late times of infection revealed in an E1B 55-kilodalton protein mutant background.

Authors:  Robin N Shepard; David A Ornelles
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  DNA-binding properties of the E1A-associated 300-kilodalton protein.

Authors:  Y Rikitake; E Moran
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  Analysis of the rat JE gene promoter identifies an AP-1 binding site essential for basal expression but not for TPA induction.

Authors:  H T Timmers; G J Pronk; J L Bos; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

5.  Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription.

Authors:  Mozhgan Rasti; Roger J A Grand; Ahmed F Yousef; Michael Shuen; Joe S Mymryk; Phillip H Gallimore; Andrew S Turnell
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

6.  Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication.

Authors:  M Kessler; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 7.  Expression and interactions of human adenovirus oncoproteins.

Authors:  P A Boulanger; G E Blair
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

8.  Molecular and functional analysis of the XPBC/ERCC-3 promoter: transcription activity is dependent on the integrity of an Sp1-binding site.

Authors:  L Ma; G Weeda; A G Jochemsen; D Bootsma; J H Hoeijmakers; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

9.  Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation.

Authors:  J A Rawls; R Pusztai; M Green
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

10.  AR1 is an integral part of the adenovirus type 2 E1A-CR3 transactivation domain.

Authors:  A C Ström; P Ohlsson; G Akusjärvi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.